METHODS AND APPARATUS FOR ARTIFICIAL EMBRYONATION AND TISSUE RECOVERY

Abstract: A process and apparatus for non-surgical recovery of ova. The process and apparatus can be used for transplanting a fertilized egg from a donor uterus to a recipient uterus, a process herein termed artificial embryonation. The apparatus is a uterine catheter (10, 20) having a semi-flexible tubular body including at least one lumen and a rounded tip portion (22, 43). Other embodiments include a double lumened catheter (41, 42) and a triple lumened catheter (52, 53, 54). The various catheters (10, 20, 50) may also be provided with inflatable uterine cuff sealing means (61). The uterine catheter(s) are used for flushing the uterus for recovering of ova.

Description: METHODS AND APPARATUS FOR ARTIFICIAL EMBRYONATION AND TISSUE RECOVERY BACKGROUND OF THE INVENTION 1 • Field of the Invention The invention relates to embryo transfer and tissue recovery processes and the apparatus therefor , and particularly to artificial embryonation and like methods which are useful for non-surgical recovery of eggs and other internal materials from a subject patient. Artificial embryonation is a term I have coined to define the disclosed transplant of a fer- tilized egg from a volunteer fertile donor to an infertile recipient. Non-surgical recovery and transfer tools are disclosed which enable this new process to be performed, as well as new uses of known compounds which enable this process to be performed for human patients. 2« Description of the Prior Art While embryo transfer has been performed in several species during the last decade, making prac¬ tical commercial use by way of substantial improvements to ideas dating back to 1893 in farm animals, only recent improvements have made the techniques possible on other than complicated experimental basis. Non- surgical techniques have not existed for transfers which do not involve rectal palpation, nor have they been possible for humans, one of those species which does not allow for such palpation. In addition, the use of steps useful in one species has proved not susceptible to general usage for a variety of factors, including lack of tools enabling more general usage and the lack of responsiveness to various compounds and media. Surgical receivery and fertilization of a human egg in vitro does appear to have been first accomplished in England in 1969 by physiologists R.G. Edwards and B.D. Bavister, and gynecologist P.C. Steptoe, by techniques and methods not fully disclosed. The claim to the birth of Louise Joy Brown on July 25, 1978, was the first recorded case in which a human egg had been surgically taken from a woman's ovary, fertil¬ ized externally and then implanted in the woman's uterus, where it developed to term. The leading and pioneer patents in the field may be reviewed in U.S. Class 128/lR and International Class A61k 17/100, and in the references cited therein and in the literature therein referenced, the state of the art of farm animals can be determined. In addition thereto, refer¬ ence may be had to the serial, Theriogenology, published by Geron-X, Inc. Los Altos, California, Science, Journal of Reproduction and Fertility, and The Biology of Reproduction The work of L.E.A.Rowsen and his associates at the A.R.C. Unit of Reproductive Physiology and Biochemistry, Animal Research Station, Cambridge, England is reported in these serials. U.S. Patent 3,854,470 issued December 17, 1974 to Augspurger , and Bovine Embryo Transfer Procedures, Colorado State University Animal Reproduction Labora¬ tory, General Series 975 (1978, 1980) represent a comprehensive disclosure of present practice, particu¬ larly as it relates to cattle, and Gravlee, U.S. Patent No. 3,527,203, issued August 4, 1970 does disclose an irrigating device for collecting tissue samples from the uterus, and Hasson, U.S. "Patent No. 3,948,270 issued April 6, 1976 discloses a uterine cannula with a rigid tube inside a Foley Catheter, similar to that used in non-surgical cattle recovery. In addition, Science, Vol. 192, pp. 1246-1247 reported the surgical transfer of a naturally inseminated Papio cyneocephalus to a naturally synchronized recipient. U.S. Patent 4,193,392 of March 19, 1980 to Barnett discloses a surgical method of ova recovery. Without detracting from the considerable reported accomplishments, it is believed that those skilled in the art appreciate that the adoption of the prior art techniques which are scattered throughout numerous sources will not yield the results reported herein, nor lead one to the novel apparatus, the new uses of known compounds, nor to the method I have used to achieve artificial embryonation and the other methods for recovery of eggs and tissue from a subject. While my apparatus is adapted to use with many mammals, and some of my methods may be employed therewith, I am particularly concerned with the problems of infertility among human couples. It has been estimated that one-third of the infertility in the United States results from disease of the Fallopian tubes, and that as many as 10 percent of all couples are infertile. In approximately 1.5 per¬ cent of all couples, both partners are infertile. The gross estimates of the number of couples so affected has been estimated to be between 500,000 and 1,000,000. Perhaps one-third of these infertile couples might have a uterus capable of accepting an embryo and carrying it to term. Due to the twin forces of birth control and legalized abortion, the number of children available for adoption by these infertile' couples has decreased dramatically. Without an alternate method, this leaves large numbers of childless couples doomed to remain that way. People who have children or who elect not to have children can scarcely understand the levels of frustration, anguish and despair that many of these couples feel. SUMMARY OF THE INVENTION The present invention provides a new, novel and heretofore unknown apparatus enabling non-surgical recovery and transfer of ova from mammal subjects which are not suitable for manual palpation. In addition, the apparatus provides unique, dual purpose capa¬ bilities as a tool for various reproductive work, such as uterine* recovery of tissue including ova for tissue culture. The present invention provides a new, and unique approach to the synchronization of the specific donor and recipient through the use of known compounds, which in other species has shown adverse side effects and abandoned. A new method of my invention allows for non- surgical transfer in smaller mammals which cannot be rectally palpated with the hand, and is particularly suitable for those of the threatened species and smaller domestic mammals, and particularly the primates and humans. The present invention of my method enables the achievement of artificial embryonation, as described. It is still another important aspect of my invention to provide a new apparatus and method for birth control in humans by the recovery of undesirable fertilized ova from a woman before it is implanted and capable of support in the womb. OREΛ " OM?I /, WIPO It will be understood that many combinations of methods described may be made, and while this introduction could be elaborated here, I feel it better to discuss my inventions in greater detail below so that a greater understanding may be had by the reader. Use of the disclosure made in the description and claims hereto, which I now make, may be subject to various combinations, modifications and rearrangements which will occur to those skilled in the art, both now, and in the future, without departing from the scope of the claims appended hereto, which are not intended to be limited, except as required by prior art. The gener¬ ally adaptable apparatus, and the special uses which I have made of known compounds, are believed to represent substantial advances in the art, as well as various methods, and the modifications thereto which I disclose. Accordingly, my disclosure will describe first the referenced drawings. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a longitudinal cross-section in a medial plane through a female human figure showing a two-lumen uterine catheter in place in the uterus. Figure 2 is an elevational view of a single lumen uterine catheter. Figure 3 is an enlarged transverse cross- sectional view on line 3-3 of Figure 2. Figure 4 is an elevational view of a two-lumen (double-lumen) uterine catheter. Figure 5 is an enlarged transverse cross- sectional view on line 5-5 of Figure 4. Figure 6 is an enlarged transverse cross- sectional view taken on line 6-6 of Figure 4. Figure 7 is an enlarged end view as shown along line 7-7 of Figure 4. Figure 8 is an elevational view of a three- lumen (triple lumen) uterine catheter. Figure 9 is an enlarged transverse cross- sectional view taken on line 9-9 of Figure 8. Figure 10 is an enlarged transverse cross-sectional view taken on line 10-10 of Figure 8. Figure 11 is an enlarged transverse cross-sectional view taken on line 11-11 of Figure 8. Figure 12 is an enlarged elevated view taken on line 12-12 of Figure 8. Figure 13 is an enlarged fragmented sectional view of the cuff portion in inflated condition. DETAILED DESCRIPTION OF THE DRAWINGS Figure 1 shows a double lumen uterine catheter 10 in place in a uterus 14, having been inserted through the cervical as 15 through the vagina 11. Markings 12 may be placed along the length of the catheter at predetermined intervals in order to determine how far into the uterus the uterine catheter has been placed. Liquid may be introduced into the uterus through the distal end of lumen 16, flowing out of port 30 into the uterus. Adapter 18 may be directly connected to a source of liquid. Liquid may be with¬ drawn from the uterus through ports 13, and allowed to flow through lumen 17. Adapter 19 may be directly connected to a source of suction to aid in withdrawal of fluid from the uterus. Figure 2 is an elevational view of a single lumen uterine catheter 20. Liquid is introduced into the adapter 24 at opening 21, flows through the uterine catheter 20, and empties into the uterus at opening 22. Markings 23 are placed along the length of the catheter 20 to aid in determining how far the catheter has entered the uterus. Figure 3 shows a transverse cross-sectional view of catheter 20. Figure 4 is an elevational view of a double lumen catheter 40. Liquid is introduced through adapter 41 and flows out of lumen 45 through opening 43 in the frontal end of the catheter. Liquid flows back from the uterus into ports 44 in lumen 46 and out through adapter 42. Markings 47 are placed along the length of catheter 40 to aid in determining how far the catheter has entered the uterus. Figure 5 is an enlarged transverse cross- sectional view along line 5-5 of Figure 4 showing lumen 42 and lumen 41 of uterine catheter 40. Figure 6 is an enlarged transverse cross- sectional view along line 6-6 of Figure 4 showing lumen 42 and lumen 41 and ports 44. Figure 7 is an enlarged end view of uterine catheter 40 along line 7-7 of Figure 4 showing lumen 41 and lumen 42 and opening 43 at the tip of uterine catheter 40. Figure 8 shows a triple lumen uterine catheter 50 showing lumens 51, 52, and 53, and balloon (cuff) 61. Fluid is introduced at the proximal end into lumen 51 through adapter 59 by means of a syringe 56. As plunger 57 is pushed down through the syringe barrel 60, fluid within the syringe barrel 60 will flow through lumen 51 out port 54 and inflate the cuff 61. As plunger 57 is removed from syringe barrel 60, negative pressure will be created in cuff 61 and fluid will flow from the cuff 61 through port 54 into lumen 51 and deflate the cuff 61. Fluid to be introduced into the uterus is introduced via uterine catheter 50 through adapter 58 through lumen 52 and out into the uterus through port 55 at the distal end. Fluid in the uterus is withdrawn -8- through por ts 56 , through lumen 53 , and out through adapter 59 . Figure 9 is an enlarged tr ansver se cross- sectional v iew along l ine 9-9 of Figure 8 showing 5 lumens 51 , 52 , and 53 of uter ine catheter 50 . Figure 10 is an enlarged tr ansver se cross- sectional view along line 10-10 of Figure 8 showing fl uid flowing out of port 54 into cuff 61 , as well as lumens 52 and 53 . 10 Figure 11 is a tr ansverse cross-sectional view along l ine 11-11 of Figure 8 showing lumen 51 , lumen 52 , and lumen 53 , and por t 56 in lumen 52. Figure 12 is an end elevational v iew along line 12-12 of Figure 8 showing lumen 52 and lumen 53 15 with port 55 . Figure 13 is an enlarged fragmentary sectional view of the cuff portion of the uterine catheter 50. Cuff 61 is an inflated condition, the inflating fluid having entered the cuff 61 through port 54 in lumen 51. 20 As described above, the uterine catheter of the present invention is of flexible, non-rigid con¬ struction in order to follow undisturbed human contours and to allow conformation with various shapes, sizes, positions, and movements found in human cervical and 25 uterine configurations. The uterine catheter possesses sufficient stiffness to permit entry by the device itself without need for a rigid stylet or stiffening rod and to prevent doubling or kinking of the tool. A ribbed construction of the wall of the catheter 20 may 30 be made to achieve the necessary serai-flexibility. The catheter is of materials such as polyvinyl chloride, polyethylene, or Teflon ® (tetrafluroethylene) . The preferred catheter is transparent and may be desirably coated with Teflon* or a silicone or similar slippery 35 resin. A method for evaluating the tubing for use in the uterine catheter of the present invention comprises measuring the deflection of the tubing, both vertically and horizontally, on a simple spring scale. A length of the tubing is held between the fingers, leaving a length of about 3 cm. exposed on one end. The free end is pressed down vertically on the scale. For suit¬ ability for use in the uterine catheter of the present invention, the tubing must possess the following characteristics: 1. The tube remains straight to a force of about 1-1/2 ounces. 2. The tube is bent to a "C" shape by a pressure of from about 4 ounces to about 8 ounces. The tubing remains straight and then suddenly gives way to a curve. The same tubing held in the same manner as above, is then applied to the scale horizontally or sideways with a 1/2 of cm. length on the scale. A force is exerted downwards into the scale by the tubing, and the tubing remains approximately flat to a force ranging from about 2 ounces to about 6 ounces. The tubing then assumes a curve on the average of 45° deflection with a force of about one ounce to about 5 ounces. The tubing remains straight, then slowly gives way to a curve. The uterine catheter may, in another embodi¬ ment, include an inflatable balloon cuff 61 for retention and blockage of flow of liquid introduced into the uterus. In this case, the uterus is not constantly irrigated, but the opening of the uterus is temporarily sealed with a small balloon, as shown in Figure 13, the uterus is inflated with the flushing liquid, and the liquid is subsequently removed using a negative pressure. The device is sufficiently soft so as to eliminate any chance of accidental perforation of the uterus. The preferred device also has, as will be noted in Figure 1 and 4, many apertures, a plurality of inlet apertures exceeding one, and a plurality of outlet ports exceeding two to enable the irrigation to be applied at a plurality of points and recovery from a plurality of points along the body of the catheter. A tool has now been described to facilitate non-surgical procedures for treating the uterus without causing discomfort to the patient. The tool, desig¬ nated as a uterine catheter, is made of a soft, slip¬ pery material in order to move smoothly through the vaginal canal. However, the catheter has sufficient rigidity to allow it to penetrate the cervical os readily, as well as sufficient flexibility to enable it to conform to the cervical and uterine contours. The uterine catheter of- the present invention is flexible to the extent that it can only be advanced stepwise about one or two centimeters at a time while held with blunt, smooth-tipped tweezers at the proximal end thereof. The uterine catheter of the present invention has a blunt, preferably bullet-shaped, nose to permit easy penetration of the cervical os or opening. The uterine catheter of the present invention has a small diameter to permit ready positioning of the catheter through the cervical os and into the uterus. The uterine catheter of the present invention has an exterior diameter of 1.6 millimeters to 4.0 milli- meters, or about 5 French to 12 French. A two lumen device is preferably about 3 millimeters in outside diameter. The uterine catheter is generally from 150 to 200 millimeters in length. The uterine catheter of the present invention can be used for a variety of non-surgical procedures for treating the uterus. For example, the uterine QMPI catheter can be used as a uterine probe, as a tool for embryo transfer, as a tool for flushing the uterus, as a tool for flushing the uterus for embryo recovery, as a tool for testing for tubal patency, for introducing a treating material into the uterus, for opening the Fallopian tubes with fluid pressure, for endometrial sampling, for the recovery of ovum (or ova) (unferti¬ lized eggs) , for recovering and sampling uterine pro¬ teins and other contents, or for genetic engineering by injecting genetic material (including DNA) into the uterus. For example, the uterus may be examined by penetrating and probing the uterus with the uterine catheter of the present invention. The uterus can be evaluated, using the uterine catheter, for ease of entry, depth, bumps, attachments, adhesions, such as scar tissue causing partial blockage, and the like. The uterine catheter may also be provided with a balloon, or several balloons of different sizes and different locations along the length of the catheter. The balloon(s) may be carefully and slowly inflated to enable the practitioner to evaluate the size and resiliency of the uterus. The uterine catheter of the present invention is particularly useful in artificial embryonation, which will be described. The uterine catheter is used to introduce washing fluid into a uterus containing an embryo or ovum. The uterine catheter is then used to remove the washing fluid containing embryo or ovum from the uterus. A positive fluid pressure is used to introduce the washing fluid into the uterus, and a negative pressure is used to remove the washing fluid plus embryo or ovum from the uterus. The washing fluid containing ovum or embryo is then introduced into a second uterus, using positive pressure through the uterine catheter of the present invention. In testing for tubal patency, a uterine catheter comprises one, two or three lumens and includes an inflatable balloon of from one to three cc. volume. The uterine catheter is slowly inserted into the uterus and the balloon is inflated and retracted, sealing the cervix against fluid leakage. A sterile fluid is slowly infused into the uterus over a period of about one to three minutes. Approximately three to 25 cc. of liquid are introduced into the uterus. The fluid that may be injected into the uterus may be a sterile salt solution such as saline; a solution of antibiotics or antiraycotics, such as penicillin, strep¬ tomycin, griseofulvin; indicating dyes, or culture media. The disappearance of the fluid into the abdom- inal cavity indicates tubal patency. A gradual buildup of pressure, and the inability to infuse more than 3 to 8 cc. of fluid into the uterus, is an indication of blocked tubes. The Fallopian tubes may be opened using the uterine catheter with inflatable balloon attached as described above, wherein the pressure is slowly increased to clear one or more blocked tubes by fluid flow. The tubes may also be washed with treating solutions. The technique is as described above for introducing liquid into the tubes, using as- the liquid a solution of a therapeutic material appropriate for the condition to be treated. Some materials that may be introduced into the uterine tubes include radio-opaque dyes, heavy oils, and therapeutic materials such as antibiotics or antimycotics. The uterine catheter can be used to change the DNA makeup of an embryo in utero, thus permitting desir- able traits to be introduced into the embryo. The OMPI *;- WIFO _ embryo is removed from the uterus by flushing the embryo-containing uterus with the uteris catheter. Additional blastomers, from a different source or individual, are micro-inserted into the embryo, or new or different DNA or RNA material is micro-inserted into the embryo. The treated embryo is then re-introduced into a uterus using the uterine catheter of the present invention. Uterine infections can be treated using the uterine catheter of the present invention by intro¬ ducing treatment materials, such as antibiotics or antimycotics, into the uterus. The infusion of the material can be continuous, using the uterine catheter without balloons. Alternatively, a uterine catheter having an inflatable balloon attachment can be used to retain the fluid infused into the uterus for a required period of time for treatment. The uterine catheter can be used to recover exfoliated endometrial cells from the uterus by intro- ducing a liquid into the uterus and withdrawing the introduced liquid plus any exfoliated endometrial cells. The exfoliated cells are then available for further analysis. In all of the above described procedures, the unique uterine catheter of the present invention can be inserted using the natural position of the cervix and the uterus with no need for repositioning of the cervix or the uterus. Because the natural position of the cervix and the uterus are used, there is no need to use a clamp or any other positioning tool. The procedures are painless to the patient because of the lack of need for repositioning the cervix or the uterus. The uterine catheter may be made of a trans¬ parent material having the suitable flexibility/rigid¬ ity characteristics in order to be able to observe the fluid contents and motion while the uterine catheter is in use. Markings shown in Figure 2 are placed " along the length of the catheter at predetermined intervals so that the uterine position may be exactly known and reproduced, particularly when the uterine catheter is used as a probe for the uterus. Now, having described in detail my uterine catheter and described some of its methods of use, I will describe my preferred methods of embryo transfer. Despite advances in embryo transfers in animals, advances from one species to another is specu¬ lative at best. Non-surgical recovery in cattle, for example, does not apply to humans. It is not possible to perform human rectal palpation and manipulation of the uterus. In the cow, the entire arm may be inserted in the rectum and the uterus lifted, positioned, and massaged. Processes that work in lower animals some¬ times don't work on higher animals. For example, prostaglandin (PG) works as a perfect abortifacient in cattle and scarcely works at all in humans. Progress is based on biological analogies, but species by species invention is still required. A different approach in embryo transfer in humans has been the use of external fertilization as an infertility treatment. The fertilization of a human egg in vitro appears first to have been accomplished in England in 1969 by physiologists R.G. Edwards and B.D. Bavister, and gynecologist P.C. Steptoe. In this first recorded case, a human egg was surgically removed from a woman's ovary, fertilized externally, and then implanted in the woman's uterus, where it developed to term. This in vitro fertilization/auto transfer (IVF/AT) specifically treats human infertility caused by blocked Fallopian tubes with a surgical method. The present technique being disclosed is a treatment for infertility which does not require surgery, and may be used for the treatment of a wider range of causes of infertility. This process, also known as artificial embryonation, involves the artificial insemination of a fertile donor with semen from the husband of the infertile recipient. The resulting child does not carry the genes of the recipient, but does carry the genes of the husband and those of the donor. The recipient, however, carries the fetus (for all but about five days) to birth. Artificial embryonation thus gives the infertile woman the opportunity to nurture and give birth to the child. Many consider this a strong bonding experience as well as fulfilling .the desire for the full measure of the experience of motherhood. Although the child does not carry the genes of the birth mother and is technically therefore not biologically related to her, it would be very difficult to convince the birthing mother that the child is not her own. The differences between human non-surgical artifical embryonation and embryo transfers presently being conducted on animals are many. In humans, the embryo donor must be fertile, but the recipient need not be fertile. The recipient need only possess a uterus which will support the growth and development of the embryo. This capability of the uterus is not affected by the non-production of eggs capable of being fertilized, as in the case of blocked Fallopian tubes. Current embryo transplantation techniques presently used for cattle require painful manipulation of both donor and recipient animals requiring local or general anesthetics. The procedure according to the present invention is a non-surgical, minimal trauma process which does not even involve dilation of the cervix or clamping of the cervix with a tenaculum. The procedure is carried out with natural cervical posi¬ tioning rather than with arbitrary cervical reposition- ing and is therefore a minimal trauma, both to donor and recipient. Embryo recovery through a flushing procedure rather than a surgical procedure is both painless and can be more efficacious. A non-surgical, minimum- trauma procedure can be performed more than once. It is easily possible, for example, to attempt to recover the fertilized embryo through flushing for four days in a row, thus increasing the opportunity to make a successful recovery. Thus, the techniques described herein are believed to be especially useful for the treatment of human infertility, when the methods, devices and compositions described are employed as indicated. The use of the processes described herein are to improve non-surgical embryo transplant, to avoid external fertilization, to treat certain forms of human infertility, and to recover assorted uterine and reproductive materials to enhance study of reproduction and medical diagnoses. Usually, it will be preferred that donor's and recipient's cycles are synchronized to within plus or minus one day with respect to time of ovulation. A detailed knowledge of each menstrual cycle is obtained. Synchronization is achieved by delaying onset of menses preferably by use of vaginal progesterone suppositories (50 mg. once or twice daily). This treatment is started at least three days before the cyclic drop in basal body temperature. Menses will begin 24-36 hours after progesterone withdrawal, and the ensuing cycle will generally be normal. Alter- 5 natively, any progestin, but typically progesterone (C-,H Q 0 ), is administered orally, topically, or parenterally, to either or both donor and recipient in order to assure that days of ovulation coincide. The support vehicle for progesterone varies depending upon 10 the type of administration, and known vehicles may be used. Alternatively, synchronization can be achieved by administration of an effective amount of a compound selected from the group of progestins, estrogens (especially estradiol-17 beta) , human chorionic 15 gonadotrophin, clomiphene citrate, follicule stimu¬ lating hormone, and mixtures thereof in a suitable support vehicle. After appropriate synchronization has been- achieved, the embryo donor is artificially inseminated 20 with semen from the husband of the infertile recipient. A deep cervical insemination is used. After fertilization, the fertilized egg moves along the oviduct, dividing as it goes. The egg usually reaches the uterus about three days later as a ~5 morula, a spherical cluster of eight or more cells. The division of the cells continues in the uterus to produce a blastocyst — a liquid-filled sphere with a group of cells, the inner cell mass, at one side. The blastocyst is surrounded by a clear, thick, gelatinous 0 .coating of proteinaceous material called the zona pellucida. The blastocyst 'floats' freely in the uterus for several days. At approximately 7-9 days, the 100-1000 cell embryo "hatches" from the zona pellucida, and then only the hatched blastocyst embryo 5 is capable of implantation, which presumably occurs within 48 hours after hatching. OI.IPI Vv'IPO Non-surgical embryo recovery involves the removal of the fertilized egg (through flushing) from the uterus, prior to implantation. Since the egg does not implant until approximately three days after entry into the uterus, the non-surgical flush can recover the embryo which can then be transferred to the recipient. A double lumen cannula tool, which I have described, is used to introduce washing fluid into the uterus as well as to remove the washing fluid and ova or embryo(s) from the uterus. A positive pressure is used to introduce the washing fluid into the uterus, and a negative pressure is used to remove the washing fluid from the uterus. The preferred flushing tool for recovery of ova or embryos has a smooth rounded tip to prevent catching of the uterus, and is preferably between 1.8 mm and 3.5 mm in external diameter. The flushing tool is of flexible, non-rigid construction in order to follow undistorted human contours and to allow conformation with various shapes, sizes, positions and movements found in human cervical and uterine configura¬ tions. The flushing tool possesses sufficient stiff¬ ness to permit entry by the device itself without need for a rigid stylet or stiffening rod and to prevent doubling or kinking the tool. A ribbed construction, which preferably is external of the catheter 20, can be used to prevent clogging. The flushing tool may be of materials such as polyvinyl chloride, polyethylene or Teflon*, or may be coated with Teflon* or silicone. The flushing tool has sufficient stiffness .that a 4 cm length will resist, without bending, a vertically applied weight of up to 15 grams; and a 4 cm length will bend under the application of a horizon¬ tally applied weight of 10 grams at a distance of 1.0 to 3.0 cm. The exterior surface of the tool, is slip- pery, with a coefficient of friction between 0.03 and 0.15. Such a tool penetrates the human uterus and yet will conform to the irregularities, shapes and sizes to be found in various human females. The flushing tool may include an inflatable cuff for retention and blockage of flow of the flushing fluid. In use, the tool does not irrigate the uterus constantly. The uterus is temporarily sealed with a small balloon, inflated with the flushing fluid, and the liquid is subsequently removed using negative pressure. The flushing involves using the medium described herein. Preferably an IV stand is employed. A flushing fluid container is placed on the stand, a tube connected between the catheter and the container , and the height of the container adjusted up or down to obtain the desired fluid column pressure. Each meter that the container is raised above the inlet is approximately l/15th of atmospheric pressure. The outlet may also be used to vary pressure by the use of a syringe to give positive or negative pressure to the outlet fluid. A combination of these procedures is normally and preferably used. The flushing fluid consists of tissue culture liquid raised to body temperature. The fertilized egg or embryo is washed out in the fluid through one channel of the flushing tool. The fluid used may be one of several suitable for culture. Examples include Dulbecco's phosphate buffered saline, PBS, as described in the Journal of Experimental Medicine, 98:167 (1954) as an aqueous solution of calcium chloride, potassium chloride, potassium dihydrogen phosphate, magnesium chloride, sodium chloride, and sodium hydrogen phosphate; and Gibco Medium 199 or TCM-199, as described in Proceedings of the Society of Experimental Biology and Medicine, 73:1 (1950) as an aqueous solution of calcium chloride, ferric nitrate, potassium chloride, potassium dihydrogen phosphate, magnesium sulfate, sodium chlor¬ ide, sodium bicarbonate, and sodium hydrogen phosphate. These media should be buffered to p„π 7.0 to 7.5 and preferably in the range of pπ 7.3 to 7.4. Additives to the basic * tissue medium may include human serum albumen (up to 20 pcercent) , human uterine protein (as flushed and filtered; between 0.02 and 10.0 percent). With other mammals, an analogous serum is preferred. Alternatively, the flushing process can be used to harvest human embryos or ova from the uterus, singly or in multiples following super-ovulation. The embryos or ova can be frozen for storage, and may then later be thawed and cultured for auto-transfer (into the woman from whom they came). After the embryo ' is flushed, the liquid culture media containing the embryo is examined under a microscope and the egg is located. Unlike cow or mouse embryos, in which the greatest numbers of transplants have been done, the human embryo is very difficult to find, since it is nearly transparent. After it is located, it is transferred to fresh media and carefully examined under a high resolution microscope for fertil- ization, division, cell structure and organization. A good embryonic developmental stage for transfer is the 500-100 cell stage. In ideal transfer conditions, the embryo may be maintained externally for a period as short as 20 to 30 minutes. If it is maintained for a longer period, the culture medium may be enhanced by modification of energy sources. As requirements of the embryo change, the culture may be modified to include glucose, fructose, pyruvate, citric acid, alpha-keto-glutorate, or ATP. Co-culturing the embryo with endometrial tissue or individual endometrial cells enhances the process. O PI The externally maintained embryo is held in an incubator in which the atmospheric environment typi¬ cally contains 0.5 to 5 percent C0-, up to 95 percent relative humidity, 5-15 percent oxygen, balanced nitrogen, and controlled temperature and temperature distribution, typically 37°, to avoid temperature shock on entry and removal. Alternatively, embryos may be frozen and stored for later use. Problems in freezing and storage of embryos involve the mechanical and biochemical destruction of cells by the expansion of water upon freezing. There¬ fore, it is essential to use cryo-protective agents which perform several functions: 1) reduce the amount of water in the cell without killing it, 2) reduce the expansion upon freezing, 3) develop uniformly distri¬ buted micro-crystals instead of a few large macro- crystals, and 4) not be poisonous in and of themselves. Freezing is done slowly to permit cellular accommodation. A final solidification often does not occur until -60 or 80°C, with many cryo-protective agents and cellular constituents. These conditions can be satisfied in whole or in part by using stepwise serial concentrations of cryo- protective agents prior to freezing and in conjunction with temperature lowering, and inversely, using step¬ wise serial dilution of cryo-protective agents upon thawing and warming. Cryo-protective agents include SMSO (dimethyl sufoxide), and glycerol. The embryo is transferred to the recipient by a flushing technique similar to that used to flush the embryo from the donor. A second small instrument is inserted through the vagina and through the cervix into the body of the uterus. The embryo is then injected into the uterus, with a small amount of culture fluid. -22- Some of the hormonal processes in oocyte maturation, ovulation, fertilization in the ampulla, oviductal transport, uterine 'float', and embryo hatching should be here noted. 5 A detailed understanding of the interrelated hormonal processes that control the female reproductive cycle has been of particular importance in developing embryonic transplants and external fertilization. The major anatomical elements involved in the cycle are the 1 0 hypothalmus near the base of the brain, the pituitary gland just below it, the ovaries, the oviduct, the uterus and the vagina. In each turn of the usual human female reproductive cycle, one egg matures, is dis¬ charged from the ovary, and passes into the expanded 15 end of the oviduct, down which it moves to the uterus. In the absence of fertilization, the egg or ova disin¬ tegrates. Without implantation, the cycle is repeated at monthly intervals. If mating or insemination has occurred at the right time in the cycle, the egg may 20 meet sperm in the oviduct at the ampulla and may become fertilized. The fertilized egg, or embryo, then moves slowly along the oviduct, nurtured and dividing as it goes. The egg usually reaches the uterus about three 25 days later as a morula — a spherical cluster of 12 or more cells. The division of the cells continues in the uterus to evolve into a blastocyst, a fluid-filled spherical body with a group of cells, the inner mass at one side. The hatched blastocyst adheres to the 30 . edometrium, the lining of the uterus — and a complex implantation process embeds the blastocyst in the uterine wall, where development continues. The inner cell mass becomes the embryo; the outer cells of the blastocyst, together with neighboring uterine cells and blood vessels, form the placenta, the organ that pro¬ vides for the exchange of materials between the later embryonic circulation and the maternal circulation. These events are regulated by the interplay of hormones produced in the hypothalmus, the pituitary, the ovaries, and the placenta. Follicle-stimulating hormone (FSH) is secreted by the pituitary, which stimulates growth of the ovum in the ovary; but as it grows, its cells secrete estrogenic hormones, chiefly estradiol, which acts on the pituitary to reduce FSH while simultaneously stimulating growth of the uterine wall and its glands. As the follicle approaches full size, FSH output decreases and a second pituitary hormone, luteinizing hormone (LH) , becomes predominant. LH completes the maturation of the egg and triggers its discharge into the oviduct. Residual follicle cells left after the discharge of the ovum secrete progesterone, which induces furthewr uterine wall development. If pregnancy does not occur, a new set of ovarian follicles grow, the corpus luteum derived from the ovulated follicle begins to decline. The resulting change in the estradiol/progesterone balance precipi¬ tates degenerative changes in the uterine wall, and menstruation occurs. If the egg has been fertilized, however, the outer cells of the developing embryo or blastocyst secrete HCG (human chorionic gonadotrophin) , a hormone which functions much like LH. This acts to prevent the .development of new follicles in the ovary. After approximately five weeks, the placenta takes over, secreting progesterone to maintain pregnancy. Superovulation can be achieved by the adminis¬ tration of FSH which causes the maturation of several follicles rather than a single one. The increased -24- frequency of human quintuplets and even sextuplets in recent years reflects the frequent administration of FSH in treating infertility due to reduced egg production. 5 The technique can also increase the availa¬ bility of eggs for in vitro fertilization or embryonic transplant. The eggs have traditionally been recovered from the ovary by laparoscopy, a surgically invasive procedure developed for diagnostic purposes. A tiny 10 telescope and a fiber-optical illuminator are intro¬ duced through a small incision in the region of the navel; the ovary and any mature follicles can be examined, and eggs can be removed, generally by aspiration, from the follicles. 1 5 External maintenance of the egg presents a problem. The egg is normally suspended in the complex biological fluids that are present in the oviduct and the uterus. Initially, there was little information about which constituents of these fluids were essential 20 for continued health of the egg. A similar problem had to be faced with the sperm, the other component of normal fertilization. The sperm are obtained in large numbers from ejaculated semen. An important obstacle had to be dealt with, 25 however, before external human fertilization could be accomplished, whether for artificial insemination of a donor female or for insemination in vitro. In the initial ejaculate, the sperm are not prepared to penetrate the egg. They must first undergo 30 .capacitation, a process that normally is induced by conditions in the female genital tract. These conditions must be simulated externally if the sperm are to be in the proper state to penetrate the egg. One of the problems associated with in vitro 35 fertilization, then, is to prove that a sperm enters an undamaged egg and that both the egg and the sperm then function normally. Although there are intermediate steps in the validation, the final test is the normal development of the zygote, or fertilized egg. In the case of eggs that normally develop externally, for example, those of starfish in seawater or of frogs in pond water, this is no great obstacle. However, for eggs that normally develop internally, the problem becomes difficult. Two options are available: The return of the egg to its normal internal environment, or the development of a suitable external environment. As a therapeutic procedure in human beings there is no question but that the first option is biologically simpler and currently far more acceptable socially. Given the close hormonal control of the normal events in ovulation, fertilization, oviductal trans¬ port, uterine maintenance, and implantation of the egg, however , it is clear that if implantation of an externally fertilized zygote is to be successful, the state of the zygote must be closely matched to the state of the uterine wall. If, for example, an egg that is fertilized after removal from a follicle develops more slowly outside the oviduct than within it, the egg might be introduced into the uterus of the recipient in too premature a state to stimulate an implantation reaction, or it might be introduced too late because the uterus is already past its optimal time for reaction. A non-surgical non-anesthetic, painless office procedure for transplanting a fertilized egg from a fertile donor human female to an infertile human female recipient is one result of our described method. This process may also be referred to as artificial embryona¬ tion, a term coined and defined by the inventors to emphasize that artificial embryonation is analogous to artificial insemination. The fertile donor may be artificially inseminated with semen from the husband of OMPI the infertile recipient. The resulting child does not carry any of the genes of the recipient, but does carry the genes of the husband and those of the donor. The recipient carries the fetus (for all but about five days) to birth. Generally, the process of the present invention is used where the donor is a fertile human and the recipient is an infertile human. Alterna¬ tively, the process according to the present invention can be used wherein an infertile couple adopts an embryo which is transplanted into the infertile wife's uterus. In this case, the embryo carries the genes of neither the wife nor the husband, and does not require fertility on the part of either husband or wife. • The process according to the present invention is also useful in the instance of a woman not capable of carrying an embryo to term. A second woman can be used as a substitute uterine carrier to carry the embryo to term for the donor of the ovum. The process of the present invention can also be used in the case wherein a donor produces a viable embryo but cannot carry it to term. In this case, the embryo can be transferred to a substitute uterine carrier, who carries the embryo to term. This process is thus useful for the case of a donor with an incom¬ petent cervix, or of a donor who because of disease or paralysis, is advised that a pregnancy would be dangerous. The process of the present invention can be used to harvest oocytes from the ovaries, singly or in multiples. The oocytes are frozen for storage, and may then later be thawed, fertilized, and cultured for auto-transfer (into the woman from which they came) or for hetero-transfer (into a woman other than the one from which they came) . The oocytes are preferably frozen and stored in liquid nitrogen. In order for the egg of a donor to be successfully transplanted into a recipient, the ovulation of both the donor and the recipient must be synchronized. Any progestin, typically progesterone I 5 may be administered vaginally, intra-uterine, orally, topically, or parenterally, to one or both of the females to delay the onset of menstruation so that the ensuing cycle days of ovulation coincide. The approximate length of the menstrual cycle 1 0 and the approximate day of ovulation within the cycle must be known for each individual. Typically, the onset of menstruation of the donor is delayed hormon- ally; sequential cycles may then be synchronized by delay of the recipient or further delay of the donor. 15 Once ovulation of both the donor and the recipient has been synchronized, the fertile donor is artifically inseminated. The uterus of the donor is then flushed to remove the resulting oocyte (fertilized egg), and the oocyte is isolated and cultured. The 20 oocyte is then non-surgically, transva inally, trans- cervically transferred to the uterus of the recipient. The differences between human non-surgical artificial embryonation and the embryo transfers presently being conducted on animals are many. -5 in the case of humans, the egg donor must be fertile, but the recipient need not be fertile - she need only possess a uterus that will support the growth and development of the embryo to term. Obviously, this capability of the uterus need not be affected by the 0 .non-production of eggs capable of being fertilized, as in the case of blocked Fallopian tubes. The embryo transplantation techniques pres¬ ently used for cattle require painful manipulation of both the donor and recipient animals, requiring a local 5 or general anesthetic. The procedure according to the present invention is absolutely painless, and does not even involve dilation of the cervix or clamping of the cervix with a tenaculum. The procedure of the present invention is carried out with natural cervical position¬ ing rather than with arbitrary cervical repositioning and therefore is a painless procedure to both the donor and the recipient. Multiple flushes of the donor's uterus to recover the oocytes are possible, because the procedure is painless and the donor is not reluctant to undergo the flushing procedure more than once. This permits flushing, for example, for four days in a row, in order to ensure recovery of a viable embryo. Preferably, a double lumen cannula tool is used to introduce washing fluid into the uterus as well as to remove the washing fluid and ova or embryos from the uterus. A positive pressure is used to introduce the washing fluid into the uterus, and a negative pressure is used to remove the washing fluid from the uterus. The preferred flushing tool, which we des- cribed, for recovery of ova or embryos has a smooth rounded tip to prevent catching of the uterus, is preferably between about 1.8 mm and about 3.5 mm in external diameter, and is of flexible, non-rigid construction in order to follow undistorted human contours and to allow conformation with various shapes, sizes, positions and movements found in human cervical and uterine configurations. The flushing tool possesses sufficient stiffness to permit entry by the device itself without need for a rigid stylet or stiffening rod and to prevent doubling or kinking of the tool. A ribbed construction on the exterior of the catheter can be used to prevent clogging. Alternatively, the flushing tool includes an inflatable cuff for retention and blockage of flow of Ol.-IFI the flushing fluid. In use, the uterus is not con¬ stantly irrigated, but the opening of the uterus is temporarily sealed with a small balloon, the uterus is inflated with the flushing fluid, and the liquid is subsequently removed using a negative pressure. In summary, artificial embryonation is a non- surgical, non-anesthetic, transcervical office pro¬ cedure for both donor and recipient. Embyro transplant is possible because of two fundamental biological phenomena: 1. There is no immune response to an embryo. Any female can carry an embryo from the same species. 2. The human embryo floats relatively freely in the uterus from approximately about the third day to the seventh day of pregnancy. The embryo does not begin to attach and bury itself in the uterine wall until about the eighth through the tenth day. Thus, the embryo can be washed or flushed out during the approximately four-day "window". The "window" period varies with species. For example, the comparable "window" for cattle is an eleven-day period from the fourth to the fifteenth day. A critical step in the embryonic transfer is the physical transfer of the fertilized egg from the donor to the recipient. A slender, curved, perforated instrument is inserted through the vagina into the uterus. A specially formulated tissue culture liquid is raised to body temperature and flushed through the tool into the uterus. The oocyte or embryo is washed out in the fluid through another channel in the flushing tool. The liquid culture media containing the oocyte is then examined under a microscope and the oocyte is located. The oocyte is transferred to fresh media in a special dish and carefully examined under a high quality microscope for fertilization, cell division, cell structure, and organization. The ideal embryo is in the 50-100 cell stage. The embryo is then transferred to the recip- ient in a manner similar to the first flushing. A second small instrument is inserted through the vagina and through the cervix into the body of the uterus. The embryo is injected in with a small amount of special culture fluid. The menstrual cycle of the donor and the recipient have been synchronized by the use of pregesterone and/or other hormones to insure similar uteral and hormonal environments for the transferred embryo. For the brief period that the embryo is outside a host body, every effort is made to keep it in an environment as similar to the body as possible. The environment for the embryo is controlled by the use of special incubators and special media. In a normal transfer, the embryo would be outside the body for between 20 and 30 minutes. The humidity, acidity and vapor pressure of carbon dioxide, and nitrogen are all carefully controlled. Alternatively, the embryo may be preserved in liquid nitrogen until it is transplanted into a recipient. The overall procedure for both donor and recipient is no more uncomfortable or hazardous than the fitting of an intro-uterine device. No surgery is involved for either the donor or the recipient. Alternatively, an oocyte may be taken from a woman who chooses to bear children at some later date, and stored in liquid nitrogen, in much the same way as sperm is stored in sperm banks. This "oocyte bank" may be of particular use to women postponing having children for professional reasons, or for women who, for reasons of convenience, prefer to save oocytes in case they change their minds after having undergone a sterilization procedure. The method used for recovery of ova may be used for preservation of the fertility of the subject which is useful, for example, when the subject desires to have the tubes ligated. The procedures for such recovery are the same as previously described, except that the oocyte or embryo (if the oocyte was fertil¬ ized) can be stored as in sperm banks by freezing also as previously described. The process which has been developed for use in ova recovery is exceptionally painless and does not involve surgery. This process allows for preventing unwanted pregnancies in humans. The process for recovery is the same process as that employed to recover ova from the uterus. The uterine catheter is stepwise inserted into the uterus, transvaginally and transcervically. The balloon is inflated. Fluid is introduced and the ova flushed and recovered before implantation and discarded. This process is used on the third or fourth day after copulation, when an unwanted pregnancy could likely occur , and may be repeated one or more of three successive days. Here I prefer to use an effective amount of ova destructive agents in the flushing medium selected from the group consisting of estrogens (estradiol-17 beta), hyperosmotic compounds, glucose, prostaglandins, acids, alkalis and urea, and mixtures thereof. These agents are normally mixed with normal saline for flushing. . Embryo transplants in humans is fraught with difficulties, risks, and problems not existing or applicable in animals. For example: a) Failure to recover the embryo results in an desirable and unwanted pregnancy in the donor. Repeat flushing and embryocidal agents described herein control this problem. b) A reverse flush (into the oviduct) can create accidental tubal pregnancy. We have developed inlet and outlet pressure control techniques to elimin¬ ate this problem. This is accomplished by using a standard IV stand with a media contained in a fluid controller, which has tubes leading to the catheter. Adjustment of the height of the container relative to the subject controls the pressure of the fluid entering the catheter. As we have said, one meter would provide an additional l/15th of atmospheric pressure to the column of fluid. The negative pressure or suction controls the outlet as previously described. We utilize pregnancy monitoring techniques in the donor to assure recovery and avoid non-uterine pregnancy. c) Twin ovulation occurs about 1 in 80, and the repeat flushes with embryocidal agents and preg¬ nancy monitoring control this problem. d) Naturally occurring ectopic pregnancy in the donor must be carefully monitored as described above. e) Particular attention must be paid to obtaining informed consent of donor and recipient for these procedures. Any procedure performed on humans requires elaborate care, precaution, and expertise that can only come from the performance of thousands of animal experiments with subjects closely approximating those of the human. I should here also state that most of the methods disclosed herein are applicable to the human .species. Species to species comparisons are not generally effective, as I have said. Particularly rodents, who do not have the cycles we are dealing with, are not good teaching tools as we have learned from experience. Likewise, the domesticated farm animal is not a good analog for much of my work. They react differently to the compounds used, and the manipulation of the reproductive tract through the rectal wall is possible particularly in cattle and horses. Nevertheless, my tools will be particularly useful in the smaller animals and those that would otherwise require surgery, particularly primates. The use of my methods and apparatus with primates particu¬ larly and with other mammals which do not allow for palpitation through the rectum is contemplated and I believe will substantially advance the treatment of these animals as well as permit non-surgical trans¬ fers. For a full understanding of my invention, reference also should be had to the disclosure of my claims which are appended hereto, drawn to my preferred and claimed inventions. These claims should be read with reference also to the foregoing inventions where I have described my preferred and alternate examples.

Claims: -34- What is claimed is: 1. A uterine catheter adapted to permit introduction of fluid into a body cavity without surgery or rectal palpation comprising: a semi-flexible substantially tubular body having a distal end and a proximal end, said tubular body having at least one proximal and one interconnected distal aperture adapted for the entry of fluid from said proximal end to said distal 10 end and allowing to exist therefrom and for recovery of said fluid from the area of the body adjacent the distal end during use, and means integral with said tubular body permitting the distal end of said body to be mani¬ 15 pulated from the proximal end to be inserted into the body of a subject and to be advanced to the desired destination within the body of the subject. 2. A uterine catheter according to Claim 1 having at least one lumen, the catheter having an open forward end and an open rear end, the forward end having a rounded tip, the catheter being iade of a material sufficiently flexible to conform to natural uterine contours and sufficiently rigid to permit insertion of the catheter into a uterus, the forward end adapted to be extended into the uterus and the rear end adapted for connection to a source of fluid, and 10 plurality of apertures spaced along the forward end position of the catheter. 3. The catheter of Claim 2 having two lumens. 4. The catheter of Claim 2 having three lumens. 5. The catheter of Claim 1 having means to seal off the opening of the uterus when the catheter is in place in the uterus. 6. The catheter in Claim 5 wherein the means to seal off the opening of the uterus is a balloon. 7. The catheter of Claim 1 wherein there are a plurality of distal apertures arranged in a spiral configuration along the end portion of the catheter. 8. The catheter of Claim 1 made of a trans¬ parent material. 9. The catheter of Claim 1 wherein markings are placed at regular intervals on the outside of the catheter. 10. A method for testing for tubal patency comprising: slowly inserting a uterine catheter having a sealing balloon into the uterus to a depth wherein the balloon is at the level of the cervix; inflating the balloon; slowly injecting from about 3 to about 25 cc. of fluid into the uterus through the uterine cath¬ eter over a period of from about one to about three minutes; observing for disappearance of the fluid indicating tubal patency, or for gradual buildup of fluid pressure indicating blocked tubes. 11. A method of opening at least one blocked uterine tube comprising: slowly inserting the uterine catheter having a sealing balloon into the uterus wherein the balloon is at the level of the cervix; inflating the balloon; slowly injecting fluid into the uterus and slowly increasing the pressure of the fluid flow until the fluid flows at a constant rate into the uterus. 12. A method for treating uterine infections comprising: slowly inserting the uterine catheter having a sealing balloon into the uterus wherein the balloon is at the level of the cervix; inflating the balloon; slowly injecting from about 3 cc. to about 25 cc. of fluid containing a suitable treating agent into the uterus; deflating the balloon; allowing the fluid to drain from the uterus. 13. A method of examining a uterus com¬ prising: slowly inserting the uterine catheter having a sealing balloon into the uterus wherein the balloon is inside the cervix; slowly inflating the balloon; evaluating the size and resiliency of the uterus based on resistance to inflating the balloon. _ . OMPI 14. A method for treating human infertility comprising: (a) synchronizing ovulation of a donor and of a recipient; (b) fertilizing an ovum of the donor by artificial insemination using sperm from the husband of the recipient to form an embryo; (c) removing the embryo from the donor; and (d) transplanting the embryo into the uterus of the recipient. 15. A method for use in recovery of ova from a subject comprising: (a) flushing the uterus directly with a catheter without rectal manipulation of the donor to obtain an embryo; (b) isolating the embryo; and (c) transferring the embryo to the uterus of a recipient. 16. The method of Claim 15 wherein the donor female and the recipient female are humans which are synchronized as to the ovulation. 17. The method of Claim 16 wherein ovulation of the donor and of the recipient is synchronized by administering of a progestin to the donor and the recipient to delay the onset of menstruation of the donor and the recipient, so that days of ovulation of the following cycle of the donor and of the recipient coincide. 18. The method of Claim 16 wherein ovulation of the donor and of the recipient is synchronized by administering progesterone to the donor and the recipient. 19. The method of Claim 18 wherein the pro¬ gesterone is administered orally. 20. The method of Claim 18 wherein the pro¬ gesterone is administered vaginally. 21. The method of Claim 18 wherein the pro¬ gesterone is administered parenterally. 22. A method for artificial embryonation comprising: (a) synchronizing ovulation of a donor human female and a recipient human female by administering progestin to a donor to delay onset of menstruation of the donor so that days of ovulation of the donor and of the recipient coincide; (b) artificially inseminating the donor, utilizing semen of husband of the infertile recipient; (c) transvaginally, transcervically flushing the uterus of the donor to obtain an embryo; (d) isolating and incubating the embryo; and (e) transvaginally, transcervically trans¬ ferring the embryo into the uterus of the recipient. 23. The method of Claim 22 wherein the pro¬ gestin is progesterone. 24. The method of Claim 22 wherein the uterus of the donor is flushed at about four days to about -seven days following artificial insemination. 25. The method of Claim 22 wherein the donor is a fertile human female and the recipient is an infertile human female. 26. The method of Claim 22 wherein the recipient is fertile but carries a genetic defect. 27. The method of Claim 22 wherein a con¬ tinuous irrigation flushing tool is used for recovery of the embryo. 28. The method of Claim 22 wherein after the embryo is isolated, the embryo is stored under liquid nitrogen prior to incubation. 29. The method of Claim 22 wherein the donor is incapable of carrying an embryo to term. 30. The method of Claim 22 wherein the donor is fertile and the recipient is fertile. 31. Uterine flushing procedure comprising con¬ tinuous irrigation of the uterus, followed by evacua¬ tion of the uterus. 32. A miniature type uterine flushing cath¬ eter having at least two lumens. 33. A method of cleaning, purifying, and sterilizing an embryo, or ovum, or oocyte by aspiration with minimum solution volume and transfer into a larger reservoir of sterile appropriate media and gently rocking and storing the dish for a few minutes and then .repeating the transfer several times into fresh media each time. 34. A method of temporarily holding an embryo for one minute to 24 hours by placing in sterile com¬ patible media but not encouraging growth. O PI 35. A method of handling and processing embryos by promoting metabolism and growth by suitable culture media and environmental atmospheric conditions for times ranging from 20 minutes to 48 hours. 36. The method of Claim 33 wherein a sequence of uterine flushes is performed at spaced intervals over 1 to 5 days to increase the probability of embryo recovery. 37. A method of synchronizing ovulation of a donor female and a recipient female wherein the ovum of the donor is frozen until the appropriate time of cycle of the recipient occurs naturally. 38. A miniature, soft, flexible tool com¬ prising three columns for fluid media: a small guard column; a small column adapted for containing ova; and a small driving fluid column; the columns each being separated by a small air gap. 39. The method of Claim 22 wherein the culture fluid media comprises: balanced salt solution; buffers to a pH of 7.0 to 7.5; nutrients; vitamins. 40. The culture fluid media of Claim 39 including endometrial cells and tissue clumps; fibro- blasts; lymphocytes, and leukocytes. 41. The method of Claim 22 wherein ovulation of the donor and of the recipient is determined by one or more ultrasonic observations and measurement of the growth and collapse of ovulating follicles. 42. A method of synchronizing ovulation of a donor and a recipient by administering to at least one of the donor and recipient a compound selected from the group consisting of progestins, estrogens, leutinizing hormone, human chorionic gonadotrophin, clomiphene citrate, follicle stimulating hormone and mixtures thereof. 43. The method of Claim 42 wherein the progestin is progestrone. 44. The method of Claim 42 wherein the estrogen is estradiol-17 beta. 45. The method of Claim 42 wherein the compound is administered orally. 46. The method of Claim 42 wherein the compound is administered vaginally. 47. The method of Claim 42 wherein the compound is administered intravenously. 48. The method of Claim 42 wherein the compound is administered parenterally. 49. The method of Claim 42 wherein the compound is administered sub-cutaneously. 50. The method of Claim 14 wherein super ovulation is induced in the donor. 51. The method of Claim 50 wherein super ovulation is induced in the donor by the administration of purified follicle stimulating hormone in sequential graded doses for a period ranging from 3 to 10 days, monitoring the response to the hormone, and adminis¬ tering leutenizing hormone to stimulate ovulation. 52. The method of Claim 14 wherein the embryo is cultured for a period ranging from about one to about eight days. 53. A method of preventing human pregnancy comprising flushing the uterus to recover an embryo prior to implantation of the embryo. 54. The method of Claim 40 wherein the flushing medium contains an effective amount of ova destructive agents selected from the group consisting of estrogens, hyperosmotic compounds, glucose, prosta- glandins, acids, alkalis, urea, and mixtures thereof. 55. A method for preserving fertility of a subject comprising removing an embryo from the uterus by flushing and freezing and storing the embryo for future use. 56. A method of preserving fertility in a female comprising: (a) determining the time of ovulation of the female; (b) flushing the uterus or oviduct of the female during ovulation to recover an ovum; (c) storing the ovum or embryo under liquid nitrogen. 57. A method of preserving fertility com¬ prising: (a) determining the time of ovulation of a donor; (b) artificially inseminating or naturally mating the donor; (c) flushing the uterus of the donor to obtain an embryo; (d) isolating the embryo; (e) storing the embryo under liquid nitrogen; (f) thawing the embryo; (g) transplanting the embryo to a fertile recipient. 58. A method of preserving tissues selected from the group consisting of embryos, ova, oocytes, and semen by freezing the tissue to liquid nitrogen tem¬ perature and storing the tissue at liquid nitrogen temperature. 59. The method of Claim 58 wherein cryo- protective agents are added. 60. The method of Claim 59 wherein the tissue is cooled at a rate of between 0.1 and 5 degrees centi¬ grade per minute. 61. The method of Claim 59 wherein the tissue is super-cooled with respect to the ice point. 62. The method of Claim 58 wherein the tissue is thawed by warming the tissue through the ice point at a rate of 0.1°C. to 5°C. per minute, sequential, graded, stepwise dilution out of the cryo-protective agent, and the slow warming to body temperature. - U- 63. The method of Claim 58 wherein the cryo- protective agent is selected from the group consisting of dimethylsulfoxide and dimethylsulfo ide glycerol. 64. The method of Claim 58 wherein the concen¬ tration of the cryo-protective agent ranges from 0.01 molar to 2 molar. 65. In a method for flushing the human female uterus, the step of using a miniature soft, flexible tool which provides three columns of fluid media: (1) a small guard column, (2) a small egg containing column; and (3) a small driving fluid column; the columns each being separated by a small air gap. 66. A method of embryo transfer, comprising: recovering an ova from the donor which may be fertilized in vitro or in the subject donor before recovery by inserting a recovery catheter into the body of the subject donor transvaginally and transcervically without rectal palpation and by manipulation of the catheter from the proximal end thereof? introducing fluid through said catheter into the uterus of the subject donor through the distal end of said catheter, and recovering said fluid together with said ova through said catheter. 67. A new use of C -.H .0 , comprising adminis¬ tering C 2i H 3 o°2 to a human female to delay the onset of menstruation. OMFI 68. In a method of embryo recovery the steps of inserting a catheter into a subject into a subject into the uterus thereof, introducing fluid through said catheter into said uterus, and adjusting the pressure of said fluid by (a) adjustment of the height of the fluid column connected to the catheter inlet or (b) by positive or negative pressure of fluid at the outlet of the catheter or (c) by a combination of (a) and (b).

Inventors: SEED RICHARD G
Applicants: SEED RICHARD G
Application year: 1981
Main classification: A61B17
IPC codes: A61B17, A61B19